Collegium Announces Scientific Presentations at PAINWeek 2018 Meeting
September 04 2018 - 10:01AM
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that
it has supported the following poster presentations on tapentadol
(Nucynta® and Nucynta® ER), at PAINWeek 2018 on September 6th in
Las Vegas.
The following posters will be presented during the poster
session on Thursday, September 6th from 6:30 pm - 8:30 pm PT:
Poster #39, presented by Dr. Janetta Iwanicki, Scientific
Director of Research and Surveillance at Rocky Mountain Poison
& Drug Center – Denver Health and Hospital Authority, is titled
"Assessment of Tapentadol API Abuse Liability with the Researched
Abuse, Diversion and Addiction-Related Surveillance (RADARS®)
System Poison Center Program". It compares the rate of intentional
abuse of tapentadol active pharmaceutical ingredient (API) to other
opioids in the RADARS System Poison Center Program.
Poster #40, presented by Dr. Jody Green, Chief Scientific
Officer at Inflexxion, an IBH Company, is titled "Nucynta ER abuse
profile: an evaluation of abuse and route of administration among
individuals receiving substance abuse treatment”. It examines the
abuse profile of Nucynta ER compared to ER opioids utilizing data
from Inflexxion’s National Addictions Vigilance Intervention and
Prevention Program (NAVIPPRO®) Addiction Severity Index–Multimedia
Version (ASI-MV®).
For more information on PAINWeek 2018, visit
http://www.painweek.org/.
About Collegium Pharmaceutical,
Inc.
Collegium is a specialty pharmaceutical company focused on
becoming the leader in responsible pain management by developing
and commercializing innovative and differentiated products for
people suffering from pain and our communities.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx
technology platform. Xtampza ER is an abuse-deterrent,
extended-release, oral formulation of oxycodone approved by the FDA
for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which
alternative treatment options are inadequate.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “should” or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
Such statements are subject to numerous important factors, risks
and uncertainties that may cause actual events or results to differ
materially from the company’s current expectations. Management’s
expectations and, therefore, any forward-looking statements in this
presentation could also be affected by risks and uncertainties
relating to a number of other factors, including the following: our
ability to obtain and maintain regulatory approval of our products
and product candidates, and any related restrictions, limitations,
and/or warnings in the label of an approved product; our plans to
commercialize and grow sales of our products; our ability to
effectively commercialize in-licensed products and manage our
relationships with licensors, including our ability to satisfy our
royalty payment obligations in connection with such products; the
size of the markets for our products and product candidates, and
our ability to service those markets; the success of competing
products that are or become available; our ability to obtain and
maintain reimbursement and third-party payor contracts for our
products; the costs of commercialization activities, including
marketing, sales and distribution; the rate and degree of market
acceptance of our products; changing market conditions for our
products; the outcome of any patent infringement or other
litigation that may be brought by or against us, including
litigation with Purdue Pharma, L.P. and Teva Pharmaceuticals USA,
Inc.; our ability to attract collaborators with development,
regulatory and commercialization expertise; the success, cost and
timing of our product development activities, studies and clinical
trials; our ability to obtain funding for our operations;
regulatory developments in the United States and foreign countries;
our expectations regarding our ability to obtain and maintain
sufficient intellectual property protection for our products and
product candidates; our ability to operate our business without
infringing the intellectual property rights of others; the
performance of our third-party suppliers and manufacturers; our
ability to secure adequate supplies of active pharmaceutical
ingredient for each of our products and product candidates; our
ability to comply with stringent U.S. and foreign government
regulations relating to the manufacturing and marketing of
pharmaceutical products, including U.S. Drug Enforcement Agency, or
DEA, compliance; the loss of key scientific or management
personnel; our expectations regarding the period during which
we qualify as an emerging growth company under the JOBS Act; our
customer concentration, which may adversely affect our financial
condition and results of operations; and the accuracy of our
estimates regarding expenses, revenue, capital requirements and
need for additional financing. These and other risks, uncertainties
and factors are described under the heading “Risk Factors” in our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2018,
and those risks described from time to time in other reports which
we file with the SEC. Any forward-looking statements that we make
in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:Alex Dasallaadasalla@collegiumpharma.com
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Apr 2023 to Apr 2024